Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ipsen will begin Phase II, proof-of-concept study designed to assess the safety and efficacy of tasquinimod in advanced or metastatic hepato-cellular, ovarian, renal cell and gastric carcinomas in patients who were already given standard anti-tumor therapies.
Subscribe to our email newsletter
The multi-centre, open-label, early stopping design study will measure the clinical activity of Tasquinimod by the section of patients with progression free survival at pre-defined time-points.
Ipsen R&D executive vice-president and chief scientific officer Claude Bertrand said tasquinimod should be assessed beyond prostate cancer due to its unique mode of action.
"We hope that this innovative, proof-of-concept study in oncology will generate data on tasquinimod’s biological and clinical activity and safety profile supporting further clinical development in high unmet medical need diseases," Bertrand added.
Tasquinimod’s immunomodulatory and anti-angiogeneic properties are applicable in addressing unmet medical need in a range of carcinomas, according to the company.